[go: up one dir, main page]

EP2653166A3 - Composition pharmaceutique pour le traitement des plaies et procédés associés - Google Patents

Composition pharmaceutique pour le traitement des plaies et procédés associés Download PDF

Info

Publication number
EP2653166A3
EP2653166A3 EP12007936.3A EP12007936A EP2653166A3 EP 2653166 A3 EP2653166 A3 EP 2653166A3 EP 12007936 A EP12007936 A EP 12007936A EP 2653166 A3 EP2653166 A3 EP 2653166A3
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
related methods
methods
wounds
cations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12007936.3A
Other languages
German (de)
English (en)
Other versions
EP2653166A2 (fr
Inventor
Tamar Tennenbaum
Liora Braiman-Wiksman
Inessa Solomonik
Ofra Levy-Hacham
Ephraim Brener
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ARAVA BIO-TECH LTD.
Original Assignee
Healor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healor Ltd filed Critical Healor Ltd
Publication of EP2653166A2 publication Critical patent/EP2653166A2/fr
Publication of EP2653166A3 publication Critical patent/EP2653166A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP12007936.3A 2007-07-30 2008-07-30 Composition pharmaceutique pour le traitement des plaies et procédés associés Withdrawn EP2653166A3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96270607P 2007-07-30 2007-07-30
EP08789725A EP2185184A2 (fr) 2007-07-30 2008-07-30 Composition pharmaceutique et procédés apparentés

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP08789725.2 Division 2008-07-30
EP08789725A Division EP2185184A2 (fr) 2007-07-30 2008-07-30 Composition pharmaceutique et procédés apparentés

Publications (2)

Publication Number Publication Date
EP2653166A2 EP2653166A2 (fr) 2013-10-23
EP2653166A3 true EP2653166A3 (fr) 2014-08-27

Family

ID=40305016

Family Applications (2)

Application Number Title Priority Date Filing Date
EP12007936.3A Withdrawn EP2653166A3 (fr) 2007-07-30 2008-07-30 Composition pharmaceutique pour le traitement des plaies et procédés associés
EP08789725A Withdrawn EP2185184A2 (fr) 2007-07-30 2008-07-30 Composition pharmaceutique et procédés apparentés

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP08789725A Withdrawn EP2185184A2 (fr) 2007-07-30 2008-07-30 Composition pharmaceutique et procédés apparentés

Country Status (10)

Country Link
US (3) US20100310542A1 (fr)
EP (2) EP2653166A3 (fr)
JP (3) JP5411857B2 (fr)
KR (2) KR20100040912A (fr)
CN (2) CN102755649A (fr)
AU (1) AU2008281374B2 (fr)
CA (1) CA2694927A1 (fr)
NZ (1) NZ582556A (fr)
RU (2) RU2502520C2 (fr)
WO (1) WO2009016629A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013885A2 (fr) 2003-08-07 2005-02-17 Healor Ltd. Compositions pharmaceutiques et methodes permettant d'accelerer la cicatrisation de plaies
WO2007026356A2 (fr) * 2005-08-29 2007-03-08 Healor Ltd. Methodes et compositions de prevention et de traitement de la peau diabetique et du vieillissement cutane
WO2011011808A1 (fr) * 2009-07-30 2011-02-03 Roman Buga Composition cosmétique comprenant du chlorure de sodium en combinaison avec et/ou au moins une protéine, un collagène, une gélatine, un acide aminé
WO2011082231A1 (fr) * 2009-12-31 2011-07-07 New York University Compositions et procédés de stimulation de l'épithélialisation et de la fermeture des plaies
WO2011083483A2 (fr) * 2010-01-11 2011-07-14 Healor Ltd. Procédé pour traiter une maladie et un trouble inflammatoires
WO2012063237A2 (fr) * 2010-11-08 2012-05-18 Healor Ltd. Compositions ophtalmiques tamponnées et leurs procédés d'utilisation
US10342891B2 (en) * 2013-09-19 2019-07-09 Medline Industries, Inc. Wound dressing containing saccharide and collagen
EA201691498A1 (ru) 2014-01-29 2017-02-28 Юниверсите Де Стразбур Новая мишень для лечения и профилактики диабета
EP3421485A1 (fr) 2017-06-30 2019-01-02 Université de Strasbourg Anticorps pour la prévention et le traitement de la thrombose
RU2766292C1 (ru) * 2021-08-05 2022-03-14 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства (ФГУП СПбНИИВС ФМБА России) Состав вакцины против covid-19

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
WO2007026356A2 (fr) * 2005-08-29 2007-03-08 Healor Ltd. Methodes et compositions de prevention et de traitement de la peau diabetique et du vieillissement cutane

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549747A (en) * 1968-02-20 1970-12-22 Flow Pharma Inc Contact lens wetting solution and method of using same
US3856919A (en) * 1970-06-08 1974-12-24 Burton Parsons Chemicals Inc Ophthalmic solution
US3947573A (en) * 1969-12-01 1976-03-30 Burton, Parsons And Company, Inc. Opthalmic solution
US3767788A (en) * 1970-06-08 1973-10-23 Burton Parsons Chemicals Inc Ophthalmic solution
US3767789A (en) * 1971-06-21 1973-10-23 Burton Parsons & Co Inc Method of providing a synthetic mucus in vivo
US3987163A (en) * 1973-07-27 1976-10-19 Burton, Parsons And Company, Inc. Polystyrene sulfonate containing opthalmic solutions
US3907985A (en) * 1973-07-27 1975-09-23 Burton Parsons And Company Inc Polystyrene sulfonate containing opthalmic solutions
US4029817A (en) * 1973-09-24 1977-06-14 Allergan Pharmaceuticals Soft contact lens preserving solutions
US3920810A (en) * 1974-04-23 1975-11-18 Burton Parsons And Company Inc Polyacrylamide containing ophthalmic solutions
US4120949A (en) * 1977-10-05 1978-10-17 Cooper Laboratories, Inc. Ophthalmic solution
US4131651A (en) * 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4558033A (en) * 1983-06-06 1985-12-10 Amgen Potentiation of the effects of insulin by peptides
US4673649A (en) * 1983-07-15 1987-06-16 University Patents, Inc. Process and defined medium for growth of human epidermal keratinocyte cells
US4940660A (en) * 1985-11-25 1990-07-10 Wako Pure Chemical Industries Color developing method in clinical examinations
US4801612A (en) * 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
US4833257A (en) * 1986-07-28 1989-05-23 Arizona Board Of Regents Compositions of matter and methods of using same
IL80298A (en) * 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
JPH0739508B2 (ja) * 1986-11-11 1995-05-01 株式会社林原生物化学研究所 プルラン・ポリエチレングリコ−ル会合物とその製造方法並びに用途
US4808402A (en) * 1987-05-29 1989-02-28 Northwestern University Method and compositions for modulating neovascularization
US5137734A (en) * 1989-03-22 1992-08-11 Dana Farber Cancer Institute Angiogenic monoglycerides
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5158935A (en) * 1989-05-12 1992-10-27 Chiron Corporation Human epidermal growth factor having substitution at position 11
US5723119A (en) * 1989-07-28 1998-03-03 Schering Corporation Method for enhancing wound healing/repair with IL-4
US5145679A (en) * 1989-10-05 1992-09-08 Hinson Joan B Topical emollient for prevention and treatment of circulatory induced lesions
US5981606A (en) * 1991-03-01 1999-11-09 Warner-Lambert Company Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same
DE69229779T2 (de) * 1991-04-19 1999-12-23 Lds Technologies, Inc. Konvertierbare mikroemulsionsverbindungen
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
HUT67319A (en) * 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
AU3062392A (en) * 1991-11-04 1993-06-07 Novo Nordisk A/S Pdgf gel formulation
US5922686A (en) * 1992-03-16 1999-07-13 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase C
US6537973B1 (en) * 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
DE4208552A1 (de) * 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh Topische arzneiformen mit insulin
GB9210574D0 (en) * 1992-05-18 1992-07-01 Ca Nat Research Council Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications
CA2125060C (fr) * 1993-07-02 1999-03-30 Henry P. Dabrowski Solution ophtalmique pour larmes artificielles
US6028118A (en) * 1996-08-08 2000-02-22 Les Laboratoires Aeterna Inc. Methods of using extracts of shark cartilage
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US5631245A (en) * 1995-06-06 1997-05-20 Biodynamics Pharmaceuticals, Inc. Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions
GB2304047A (en) * 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
EP1295952A3 (fr) * 1996-01-23 2003-07-09 The Board of Trustees of The Leland Stanford Junior University Méthodes de criblage de peptides effecteurs transdominantes et des molécules ARN
US5869037A (en) * 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
GB9702943D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Wound healing
US6274712B1 (en) * 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
FR2773075B1 (fr) * 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
DE69924232D1 (de) * 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
US6790207B2 (en) * 1998-06-04 2004-09-14 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract
US6489306B2 (en) * 1998-02-23 2002-12-03 University Of South Florida Method of intranasal gene transfer for protection against respiratory infection
DE19826628C1 (de) * 1998-06-17 2000-07-20 Werner Kern Intranasale Verwendung von Insulin bei Hirnleistungsstörungen
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
WO2000005250A1 (fr) * 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Traitement de maladies auto-immunes a l'aide du copolymere 1 et des copolymeres et peptides apparentes
US6096288A (en) * 1998-10-12 2000-08-01 Mobil Oil Corporation Synthesis of the cubic mesoporous molecular sieve MCM-48
AU1740900A (en) * 1998-11-20 2000-06-13 Genentech Inc. Method of inhibiting angiogenesis
US7261881B1 (en) * 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
US6541447B1 (en) * 1999-09-01 2003-04-01 B & M Healthcare Technologies, Inc. Wound healing composition and method for use thereof
US7074408B2 (en) * 2000-02-25 2006-07-11 Immunex Corporation Use of integrin antagonists to inhibit angiogenesis
JP2003528926A (ja) * 2000-03-24 2003-09-30 ノバルティス アクチエンゲゼルシャフト 新血管形成の改善された処置
WO2001076650A1 (fr) * 2000-04-06 2001-10-18 University Technology Corporation Compositions et methodes visant a favoriser la cicatrisation
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
ATE429925T1 (de) * 2000-07-31 2009-05-15 Univ Bar Ilan Methoden und pharmazeutische zusammensetzungen zur wundheilung
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
GB2369572A (en) * 2000-11-29 2002-06-05 Raft Trustees Ltd Wound treatment composition comprising insulin
JP2002198443A (ja) * 2000-12-26 2002-07-12 Nec Corp 半導体装置及びその製造方法
US20020119914A1 (en) * 2000-12-26 2002-08-29 Deguang Zhu New uses of insulin and pancreatin
GB0103877D0 (en) * 2001-02-16 2001-04-04 King S College London Novel Drug Delivery system
DE10109280A1 (de) * 2001-02-26 2002-09-05 Peter Mayser Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen
KR100404072B1 (ko) * 2001-03-12 2003-11-03 주식회사 두산 광범위 피부질환 치료용 조성물
US20030091601A1 (en) * 2001-11-13 2003-05-15 Abat Inc. Use of topical arginine to enhance wound healing
US20030124503A1 (en) * 2001-12-28 2003-07-03 Olivencia-Yurvati Albert H. Pyruvate cardioplegia solutions for administration to the heart during cardiopulmonary surgery and methods of use thereof
AU2003209226A1 (en) * 2002-01-11 2003-07-30 Michael Tennant Adiponectin gene therapy
RU2249467C2 (ru) * 2002-11-25 2005-04-10 ООО Научно-производственное предприятие "ЭРЛОН", Лтд. Медицинский материал и изделия на его основе
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
SE0300207D0 (sv) * 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
US7190893B2 (en) * 2003-06-27 2007-03-13 Valeo Electrical Systems, Inc. Fluid heater with low porosity thermal mass
JP4790609B2 (ja) * 2003-07-15 2011-10-12 バーイラン ユニバーシティー 創傷治癒のための方法及び薬剤組成物
WO2005013885A2 (fr) * 2003-08-07 2005-02-17 Healor Ltd. Compositions pharmaceutiques et methodes permettant d'accelerer la cicatrisation de plaies
WO2005062918A2 (fr) * 2003-12-24 2005-07-14 Wyeth Methodes permettant de traiter l'asthme
US7902330B2 (en) * 2004-02-13 2011-03-08 Albert Einstein College Of Medicine Of Yeshiva University Protein kinase inhibitors and methods for identifying same
EP1877424A4 (fr) * 2005-04-11 2010-09-29 Pharmagap Inc Inhibiteurs de protéines kinases et leurs utilisations
CA2659961A1 (fr) * 2005-08-05 2007-02-15 Pharmagap Inc. Inhibiteurs de proteine kinase c cibles et leurs utilisations
NZ566551A (en) * 2005-08-19 2011-09-30 Emisphere Tech Inc Cyclopropyl compounds and compositions for delivering active agents
US20090306045A1 (en) * 2005-12-22 2009-12-10 Ira Mellman Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease
US20080292726A1 (en) * 2007-01-23 2008-11-27 Bernstein Lawrence R Ophthalmic gallium compositions and methods of their use
WO2010029350A1 (fr) * 2008-09-09 2010-03-18 University Of East Anglia Traitement de troubles fibrotiques de l’œil
ES2601827T3 (es) * 2009-02-24 2017-02-16 Arava Bio-Tech Ltd. Agentes antagonistas de visfatina para el tratamiento del acné y de otras afecciones

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
WO2007026356A2 (fr) * 2005-08-29 2007-03-08 Healor Ltd. Methodes et compositions de prevention et de traitement de la peau diabetique et du vieillissement cutane

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YULI M ET AL: "Innovative PKC modulating formulation dramatically improves the healing of diabetic wounds", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, NATURE PUBLISHING GROUP, GB, vol. 122, no. 3, 1 March 2004 (2004-03-01), pages A49, XP009121582, ISSN: 0022-202X *

Also Published As

Publication number Publication date
CA2694927A1 (fr) 2009-02-05
CN101835486A (zh) 2010-09-15
JP5411857B2 (ja) 2014-02-12
CN102755649A (zh) 2012-10-31
US20100310542A1 (en) 2010-12-09
CN101835486B (zh) 2012-12-12
JP2013144697A (ja) 2013-07-25
EP2185184A2 (fr) 2010-05-19
HK1148467A1 (en) 2011-09-09
RU2010106661A (ru) 2011-09-10
KR20130121678A (ko) 2013-11-06
WO2009016629A3 (fr) 2009-05-22
NZ582556A (en) 2013-02-22
KR20100040912A (ko) 2010-04-21
JP2010535194A (ja) 2010-11-18
JP2014024862A (ja) 2014-02-06
WO2009016629A2 (fr) 2009-02-05
US20130336952A1 (en) 2013-12-19
EP2653166A2 (fr) 2013-10-23
RU2502520C2 (ru) 2013-12-27
AU2008281374B2 (en) 2012-05-31
AU2008281374A1 (en) 2009-02-05
US20140227243A1 (en) 2014-08-14
RU2013142159A (ru) 2015-03-27

Similar Documents

Publication Publication Date Title
EP2653166A3 (fr) Composition pharmaceutique pour le traitement des plaies et procédés associés
EP2314323A3 (fr) Composition chirurgicale bioabsorbable
WO2012088266A3 (fr) Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
WO2009100280A3 (fr) Compositions d'hydroxyapatite et de soie en trois dimensions
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
MY169564A (en) Substituted dihydropyrazolones and their use
WO2013036525A3 (fr) Ciments osseux à plusieurs pâtes et résorbables, compositions hémostatiques, et procédés d'utilisation
IN2012DN00971A (fr)
WO2007109172A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2010055082A3 (fr) Nouvelle forme cristalline de malate de sunitinib
GEP20135786B (en) Pyrrole compounds
WO2007109154A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 modulators et leurs utilisations
IN2014KN01075A (fr)
WO2009147075A3 (fr) Compositions pharmaceutiques contenant une forme cristalline de posaconazole
WO2007109160A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
IL210997A (en) Preparations for the treatment of mrsa and their uses for the preparation of medicines
GEP201606513B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
WO2007109279A3 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
WO2010033977A3 (fr) Composes multiheteroaryles servant d'inhibiteurs de la h-pgds, ainsi que leur utilisation dans le traitement des maladies induites par la prostaglandine d2
WO2007109182A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2011149993A3 (fr) Octahydrocyclopenta [c] pyrroles substitués utilisés en tant que modulateurs des canaux calciques
WO2011023367A3 (fr) Promédicaments bisphosphonates
EP2540301A3 (fr) Procédés et compositions pharmaceutiques servant à guérir des blessures
TW200738659A (en) Novel compounds
TW200730518A (en) Crystalline forms of docetaxel and processes for their preparation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121126

AC Divisional application: reference to earlier application

Ref document number: 2185184

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/17 20060101ALI20140723BHEP

Ipc: A61K 31/403 20060101ALI20140723BHEP

Ipc: A61K 38/08 20060101ALI20140723BHEP

Ipc: A61K 31/7088 20060101ALI20140723BHEP

Ipc: A61K 31/553 20060101ALI20140723BHEP

Ipc: A61P 17/02 20060101ALI20140723BHEP

Ipc: A61K 38/28 20060101AFI20140723BHEP

Ipc: A61K 31/404 20060101ALI20140723BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ARAVA BIO-TECH LTD.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150228